الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Multiple myeloma is a malignancy of plasma cells in the bone marrow and Prohibitin (PHB) is a mitochondrial protein that is encoded by the PHB gene on the BRCA1 and functions as a tumour suppressor gene as well as having anti-apoptotic properties
Mutation or turning off tumour-suppression genes is one of mechanisms involved in the development of cancer.
This study was conducted on 50 multiple myeloma patients, we measured the serum level of prohibitin before autologous bone marrow transplant and post-transplant on day 28 and correlated them together.
In this study, we measured the serum level of prohibitn pre and posttransplant that was a highly statistically significant lower in post-transplant compared to pre-transplant, the pretransplant serum prohibitin level showed that level was statistically higher in dead patients than in living patients. And significant difference between the number of people who went into complete remission and those who came back after a transplant.
The Patients who relapsed post-transplant had nearly double the expression of prohibitin than those who remained in remission
Conclusion and Recommendations
Conclusion
1. Prohibitin level is high in MM and has high sensitivity and specificity prognostic marker for MM.
2. Transplantation lead to marked decrease in prohibtin level
3. High level of prohibitin pre-transplant associated with poor outcome and prognosis than low level pre transplant
Recommendations
1. Perform the study on a larger scale of MM patients with longer period of follow up.
2. Analyze the prognostic impact of Prohibitin level in treated MM patients.
3. Study the exact patho-physiological role of Prohibitin in MM.
4. correlate Prohibitin level with other prognostic markers, e.g. t(11;14), t(4;14), t(14;16), t(6;14), t (14;20), trisomies, and del(17p), … etc.
5. Anti prohibitin could be investigated as targeted therapy in MM patients